An US institutional investor acquired 3% stake in Motif Bio plc (AIM:MTFB) from Amphion Innovations Plc (AIM:AMP) for $3.7 million on May 22, 2018. Under the terms of agreement, Amphion Innovations sold 8.896 million shares of Motif Bio at £0.31 ($0.413931) per share. Following this sale, Amphion's holding will represent 9.53% of the issued share capital of Motif. The net proceeds from the sale will be used as partial repayment of the loan facility. Freddy Crossley, Emma Earl and Charlie Leigh-Pemberton of Panmure Gordon Limited acted as financial advisor and broker for Amphion Innovations. David Hignell and John Howes of Northland Capital Partners Limited acted as broker for Amphion Innovations. Christopher Golden and Oliver Jackson of Peel Hunt LLP acted as financial advisor and broker for Motif Bio. David Hignell, John Howes, Rob Rees of Northland Capital Partners Limited acted as broker for Motif Bio.

An US institutional investor completed the acquisition of 3% stake in Motif Bio plc (AIM:MTFB) from Amphion Innovations Plc (AIM:AMP) on May 22, 2018.